Q32 Bio Shares Plummet After Downgrades, Price Target Cuts

MT Newswires Live

Dec 12, 2024

Q32 Bio (QTTB) shares fell past 71% in recent trading Wednesday after multiple downgrades and price target cuts following results from the company's mid-stage clinical trial of atopic dermatitis treatment.

The company earlier said its SIGNAL-AD clinical trial in atopic dermatitis failed to meet the primary endpoint in Part B after demonstrating promising findings in Part A. At week 14, data from Part B showed patients treated with bempikibart showed a 74% improvement in the average Eczema Area and Severity Index from baseline, compared with 76% for the placebo group.

Guggenheim downgraded the stock to neutral from buy, and Leerink Partners downgraded it to market perform from outperform, while also cutting its price target to $9 from $68. Wells Fargo downgraded the company to equal weight from overweight and adjusted its price target to $16 from $95, while Raymond James downgraded it to outperform from strong buy and slashed its price target to $22 from $90. Oppenheimer maintained its outperform rating on Q32 Bio, but lowered its price target to $20 from $80.

Price: 7.00, Change: -17.41, Percent Change: -71.32

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2490893609"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490893609\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2490893609?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 01:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490893609","market":"fut","top_or_hot":-1,"title":"Q32 Bio Shares Plummet After Downgrades, Price Target Cuts","media":"MT Newswires Live","content":"<html><body><p> Q32 Bio (QTTB) shares fell past 71% in recent trading Wednesday after multiple downgrades and price target cuts following results from the company's mid-stage clinical trial of atopic dermatitis treatment.</p><p>The company earlier said its SIGNAL-AD clinical trial in atopic dermatitis failed to meet the primary endpoint in Part B after demonstrating promising findings in Part A. At week 14, data from Part B showed patients treated with bempikibart showed a 74% improvement in the average Eczema Area and Severity Index from baseline, compared with 76% for the placebo group.</p><p>Guggenheim downgraded the stock to neutral from buy, and Leerink Partners downgraded it to market perform from outperform, while also cutting its price target to $9 from $68. Wells Fargo downgraded the company to equal weight from overweight and adjusted its price target to $16 from $95, while Raymond James downgraded it to outperform from strong buy and slashed its price target to $22 from $90. Oppenheimer maintained its outperform rating on Q32 Bio, but lowered its price target to $20 from $80.</p><p>Price: 7.00, Change: -17.41, Percent Change: -71.32</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Q32 Bio Shares Plummet After Downgrades, Price Target Cuts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQ32 Bio Shares Plummet After Downgrades, Price Target Cuts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-12 01:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Q32 Bio (QTTB) shares fell past 71% in recent trading Wednesday after multiple downgrades and price target cuts following results from the company's mid-stage clinical trial of atopic dermatitis treatment.</p><p>The company earlier said its SIGNAL-AD clinical trial in atopic dermatitis failed to meet the primary endpoint in Part B after demonstrating promising findings in Part A. At week 14, data from Part B showed patients treated with bempikibart showed a 74% improvement in the average Eczema Area and Severity Index from baseline, compared with 76% for the placebo group.</p><p>Guggenheim downgraded the stock to neutral from buy, and Leerink Partners downgraded it to market perform from outperform, while also cutting its price target to $9 from $68. Wells Fargo downgraded the company to equal weight from overweight and adjusted its price target to $16 from $95, while Raymond James downgraded it to outperform from strong buy and slashed its price target to $22 from $90. Oppenheimer maintained its outperform rating on Q32 Bio, but lowered its price target to $20 from $80.</p><p>Price: 7.00, Change: -17.41, Percent Change: -71.32</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QTTB","symbol_name":"Q32 Bio Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490893609","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490893609","pubTimestamp":1733938474,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Q32 Bio  shares fell past 71% in recent trading Wednesday after multiple downgrades and price target cuts following results from the company's mid-stage clinical trial of atopic dermatitis treatment.The company earlier said its SIGNAL-AD clinical trial in atopic dermatitis failed to meet the primary endpoint in Part B after demonstrating promising findings in Part A. At week 14, data from Part B showed patients treated with bempikibart showed a 74% improvement in the average Eczema Area and Severity Index from baseline, compared with 76% for the placebo group.Guggenheim downgraded the stock to neutral from buy, and Leerink Partners downgraded it to market perform from outperform, while also cutting its price target to $9 from $68. Wells Fargo downgraded the company to equal weight from overweight and adjusted its price target to $16 from $95, while Raymond James downgraded it to outperform from strong buy and slashed its price target to $22 from $90. Oppenheimer maintained its outperfo","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"QTTB":"Q32 Bio Inc."},"translate_title":"Q32生物股价在评级下调、目标价下调后暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTTB":0.9},"content_text":"Q32 Bio (QTTB) shares fell past 71% in recent trading Wednesday after multiple downgrades and price target cuts following results from the company's mid-stage clinical trial of atopic dermatitis treatment.The company earlier said its SIGNAL-AD clinical trial in atopic dermatitis failed to meet the primary endpoint in Part B after demonstrating promising findings in Part A. At week 14, data from Part B showed patients treated with bempikibart showed a 74% improvement in the average Eczema Area and Severity Index from baseline, compared with 76% for the placebo group.Guggenheim downgraded the stock to neutral from buy, and Leerink Partners downgraded it to market perform from outperform, while also cutting its price target to $9 from $68. Wells Fargo downgraded the company to equal weight from overweight and adjusted its price target to $16 from $95, while Raymond James downgraded it to outperform from strong buy and slashed its price target to $22 from $90. Oppenheimer maintained its outperform rating on Q32 Bio, but lowered its price target to $20 from $80.Price: 7.00, Change: -17.41, Percent Change: -71.32","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}